Literature DB >> 17968485

Involvement of alpha(v)beta3 integrins in osteoclast function.

Ichiro Nakamura1, Le T Duong, Sevgi B Rodan, Gideon A Rodan.   

Abstract

Integrins are heterodimeric adhesion receptors that mediate cell-matrix interaction. Osteoclast exhibits high expression of the alpha(v)beta(3) integrin, which binds to a variety of extracellular matrix proteins including vitronectin, osteopontin, and bone sialoprotein. Arg-Gly-Asp (RGD)-containing peptides, RGD-mimetics, and blocking antibodies to alpha(v)beta(3) integrin were shown to inhibit bone resorption in vitro and in vivo, suggesting that this integrin may play an important role in regulating osteoclast function. Several lines of evidence have demonstrated that a number of signaling molecules are involved in the alpha(v)beta(3) integrin-dependent signaling pathway, including c-Src, Pyk2, c-Cbl, and p130(Cas). In this article, we review the history of "alpha(v)beta(3) integrin and osteoclasts" and discuss the involvement of alpha(v)beta(3) integrins in osteoclast function at tissue, cellular, and molecular levels. A better understanding of the role of alpha(v)beta(3) integrin in osteoclastic bone resorption would provide opportunities for developing new therapeutics to treat human bone diseases, including rheumatoid arthritis, osteoporosis, and periodontal disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17968485     DOI: 10.1007/s00774-007-0773-9

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  55 in total

1.  TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src.

Authors:  B R Wong; D Besser; N Kim; J R Arron; M Vologodskaia; H Hanafusa; Y Choi
Journal:  Mol Cell       Date:  1999-12       Impact factor: 17.970

2.  Arg-Gly-Asp (RGD) peptides and the anti-vitronectin receptor antibody 23C6 inhibit dentine resorption and cell spreading by osteoclasts.

Authors:  M A Horton; M L Taylor; T R Arnett; M H Helfrich
Journal:  Exp Cell Res       Date:  1991-08       Impact factor: 3.905

Review 3.  Bone resorption by osteoclasts.

Authors:  S L Teitelbaum
Journal:  Science       Date:  2000-09-01       Impact factor: 47.728

4.  c-Cbl is downstream of c-Src in a signalling pathway necessary for bone resorption.

Authors:  S Tanaka; M Amling; L Neff; A Peyman; E Uhlmann; J B Levy; R Baron
Journal:  Nature       Date:  1996-10-10       Impact factor: 49.962

5.  An interleukin 1 like factor stimulates bone resorption in vitro.

Authors:  M Gowen; D D Wood; E J Ihrie; M K McGuire; R G Russell
Journal:  Nature       Date:  1983 Nov 24-30       Impact factor: 49.962

6.  Inhibition of osteoclastic bone resorption in vivo by echistatin, an "arginyl-glycyl-aspartyl" (RGD)-containing protein.

Authors:  J E Fisher; M P Caulfield; M Sato; H A Quartuccio; R J Gould; V M Garsky; G A Rodan; M Rosenblatt
Journal:  Endocrinology       Date:  1993-03       Impact factor: 4.736

7.  Role of alpha(v)beta(3) integrin in osteoclast migration and formation of the sealing zone.

Authors:  I Nakamura; M F Pilkington; P T Lakkakorpi; L Lipfert; S M Sims; S J Dixon; G A Rodan; L T Duong
Journal:  J Cell Sci       Date:  1999-11       Impact factor: 5.285

8.  The osteoclast functional antigen, implicated in the regulation of bone resorption, is biochemically related to the vitronectin receptor.

Authors:  J Davies; J Warwick; N Totty; R Philp; M Helfrich; M Horton
Journal:  J Cell Biol       Date:  1989-10       Impact factor: 10.539

9.  Integrin subunit expression by human osteoblasts and osteoclasts in situ and in culture.

Authors:  J Clover; R A Dodds; M Gowen
Journal:  J Cell Sci       Date:  1992-09       Impact factor: 5.285

10.  Osteoclasts express high levels of pp60c-src in association with intracellular membranes.

Authors:  W C Horne; L Neff; D Chatterjee; A Lomri; J B Levy; R Baron
Journal:  J Cell Biol       Date:  1992-11       Impact factor: 10.539

View more
  71 in total

1.  Role of osteopontin in early phase of renal crystal formation: immunohistochemical and microstructural comparisons with osteopontin knock-out mice.

Authors:  Masahito Hirose; Keiichi Tozawa; Atsushi Okada; Shuzo Hamamoto; Yuji Higashibata; Bin Gao; Yutaro Hayashi; Hideo Shimizu; Yasue Kubota; Takahiro Yasui; Kenjiro Kohri
Journal:  Urol Res       Date:  2011-08-11

2.  Osteopontin is up-regulated and associated with neutrophil and macrophage infiltration in glioblastoma.

Authors:  Nadia A Atai; Manju Bansal; Cheungh Lo; Joost Bosman; Wikky Tigchelaar; Klazien S Bosch; Ard Jonker; Philip C De Witt Hamer; Dirk Troost; Christopher A McCulloch; Vincent Everts; Cornelis J F Van Noorden; Jaro Sodek
Journal:  Immunology       Date:  2010-08-17       Impact factor: 7.397

3.  RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications.

Authors:  Antonio Garcia-Gomez; Enrique M Ocio; Atanasio Pandiella; Jesús F San Miguel; Mercedes Garayoa
Journal:  Invest New Drugs       Date:  2012-07-07       Impact factor: 3.850

4.  DEL-1 restrains osteoclastogenesis and inhibits inflammatory bone loss in nonhuman primates.

Authors:  Jieun Shin; Tomoki Maekawa; Toshiharu Abe; Evlambia Hajishengallis; Kavita Hosur; Kalyani Pyaram; Ioannis Mitroulis; Triantafyllos Chavakis; George Hajishengallis
Journal:  Sci Transl Med       Date:  2015-09-30       Impact factor: 17.956

Review 5.  Notch and the regulation of osteoclast differentiation and function.

Authors:  Jungeun Yu; Ernesto Canalis
Journal:  Bone       Date:  2020-06-08       Impact factor: 4.398

6.  The Rac1 exchange factor Dock5 is essential for bone resorption by osteoclasts.

Authors:  Virginie Vives; Mélanie Laurin; Gaelle Cres; Pauline Larrousse; Zakia Morichaud; Danièle Noel; Jean-François Côté; Anne Blangy
Journal:  J Bone Miner Res       Date:  2011-05       Impact factor: 6.741

7.  Enhanced osteoblast and osteoclast responses to a thin film sputtered hydroxyapatite coating.

Authors:  J Hao; S Kuroda; K Ohya; S Bartakova; H Aoki; S Kasugai
Journal:  J Mater Sci Mater Med       Date:  2011-05-13       Impact factor: 3.896

8.  Lack of Myosin X Enhances Osteoclastogenesis and Increases Cell Surface Unc5b in Osteoclast-Lineage Cells.

Authors:  Bo Wang; Jin-Xiu Pan; Huali Yu; Lei Xiong; Kai Zhao; Shan Xiong; Jun-Peng Guo; Sen Lin; Dong Sun; Lu Zhao; Haohan Guo; Lin Mei; Wen-Cheng Xiong
Journal:  J Bone Miner Res       Date:  2019-02-19       Impact factor: 6.741

Review 9.  Current, new and future treatments of osteoporosis.

Authors:  Pooneh Salari Sharif; Mohammad Abdollahi; Bagher Larijani
Journal:  Rheumatol Int       Date:  2010-07-30       Impact factor: 2.631

10.  Response of human pancreatic cancer cell xenografts to tetraiodothyroacetic acid nanoparticles.

Authors:  Murat Yalcin; Hung-Yun Lin; Thangirala Sudha; Dhruba J Bharali; Ran Meng; Heng-Yuan Tang; Faith B Davis; Steven C Stain; Paul J Davis; Shaker A Mousa
Journal:  Horm Cancer       Date:  2013-02-28       Impact factor: 3.869

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.